Compare FSP & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSP | CRDF |
|---|---|---|
| Founded | 1981 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.4M | 86.8M |
| IPO Year | 2001 | 2012 |
| Metric | FSP | CRDF |
|---|---|---|
| Price | $0.43 | $0.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.63 |
| AVG Volume (30 Days) | 340.1K | ★ 1.6M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.34% | N/A |
| EPS Growth | 15.69 | ★ 27.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $107,162,000.00 | $365,993.00 |
| Revenue This Year | $17.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $0.43 | $0.80 |
| 52 Week High | $1.82 | $3.80 |
| Indicator | FSP | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 31.24 | 27.54 |
| Support Level | N/A | N/A |
| Resistance Level | $0.70 | $2.03 |
| Average True Range (ATR) | 0.02 | 0.08 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 1.88 | 3.63 |
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.